Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK
Context Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia. Objective This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats. Materials and methods Adult male Wistar rats (130 ± 10...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_e4c34b51b708424ca2b701e8970618e6 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Jozaa Z. ALTamimi |e author |
700 | 1 | 0 | |a Ghedeir M. Alshammari |e author |
700 | 1 | 0 | |a Nora A. AlFaris |e author |
700 | 1 | 0 | |a Reham I. Alagal |e author |
700 | 1 | 0 | |a Dalal H. Aljabryn |e author |
700 | 1 | 0 | |a Norah A. Albekairi |e author |
700 | 1 | 0 | |a Mahmoud Ahmad Alkhateeb |e author |
700 | 1 | 0 | |a Mohammed Abdo Yahya |e author |
245 | 0 | 0 | |a Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK |
260 | |b Taylor & Francis Group, |c 2022-01-01T00:00:00Z. | ||
500 | |a 1388-0209 | ||
500 | |a 1744-5116 | ||
500 | |a 10.1080/13880209.2021.1990969 | ||
520 | |a Context Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia. Objective This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats. Materials and methods Adult male Wistar rats (130 ± 10 g) were divided into 6 groups (n = 8 rats/group) as control, control + EA, control + EA + CC an AMPK inhibitor), T1DM, T1DM + EA, and T1DM + EA + CC. The treatments with EA (50 mg/kg/orally) and CC (200 ng/rat/i.p.) were given the desired groups for 12 weeks, daily. Results In T1DM-rats, EA reduced fasting glucose levels (44.8%), increased fasting insulin levels (92.8%), prevented hepatic lipid accumulation, and decreased hepatic and serum levels of total triglycerides (54% & 61%), cholesterol (57% & 48%), and free fatty acids (40% & 37%). It also reduced hepatic levels of ROS (62%), MDA (52%), TNF-α (62%), and IL-6 (57.2%) and the nuclear activity of NF-κB p65 (54%) but increased the nuclear activity of Nrf-2 (4-fold) and levels of GSH (107%) and SOD (87%). Besides, EA reduced downregulated SREBP1 (35%), SREBP2 (34%), ACC-1 (36%), FAS (38%), and HMG-CoAR (49%) but stimulated mRNA levels of PPARα (1.7-fold) and CPT1a (1.8-fold), CPT1b (2.9-fold), and p-AMPK (4-fold). All these events were prevented by the co-administration of CC. Discussion and conclusions These findings encourage the use of EA to treat hepatic disorders, and non-alcoholic fatty liver disease (NAFLD). Further in vivo and in vitro studies are needed to validate its potential in clinical medicine. | ||
546 | |a EN | ||
690 | |a t1dm | ||
690 | |a nafld | ||
690 | |a polyphenols | ||
690 | |a oxidative stress | ||
690 | |a inflammation | ||
690 | |a lipid metabolism | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutical Biology, Vol 60, Iss 1, Pp 25-37 (2022) | |
787 | 0 | |n http://dx.doi.org/10.1080/13880209.2021.1990969 | |
787 | 0 | |n https://doaj.org/toc/1388-0209 | |
787 | 0 | |n https://doaj.org/toc/1744-5116 | |
856 | 4 | 1 | |u https://doaj.org/article/e4c34b51b708424ca2b701e8970618e6 |z Connect to this object online. |